MarlynJean(Krampitz)MayoMD
Gastroenterology • Dallas, TXHepatology & Liver Transplantation
Professor of Medicine, University Tex SW Dallas
Dr. Mayo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-645-8600Fax+1 214-645-0596
Education & Training
University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 1993 - 1996
University of California (Irvine)Residency, Internal Medicine, 1990 - 1993
Baylor College of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1992 - Present
TX State Medical License 1992 - 2026- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow (AGAF) American Gastroenterological Association, 2011
Clinical Trials
- Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 4 citationsPrimary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?David E J Jones, Ulrich Beuers, Alan Bonder, Marco Carbone, Emma Culver
Hepatology. 2024-11-01 - 1 citationsPrognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.Aldo J Montano-Loza, Ellina Lytvyak, Gideon Hirschfield, Bettina E Hansen, Maryam Ebadi
Journal of Hepatology. 2024-10-01 - Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.Surain B Roberts, Woo Jin Choi, Lawrence Worobetz, Catherine Vincent, Jennifer A Flemming
JHEP Reports. 2024-10-01
Journal Articles
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver DiseasesMarlyn (Krampitz) Mayo, MD, Hepatology
Authored Content
- The Liver Meeting's Highlights and LowlightsNovember 2023
Press Mentions
Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin DeficiencyOctober 11th, 2024- Study Outlines Risk Factors for Autoimmune Hepatitis After Liver TransplantMay 20th, 2022
- CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary CholangitisNovember 11th, 2021
- Join now to see all
Grant Support
- Ursodeoxycholic Acid (UDCA) In Primary Biliary CirrhosisNational Center For Research Resources2007
- UDCA Amp;Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2007
- Treatment Of Metabolic PruritisNational Center For Research Resources2004–2007
- UDCA &Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2006
- Longitudinal Studies Of Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
- 1treatment Of Cholestatic Pruritus With SertralineNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
- Role Of CD40-CD40 Ligand In Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2003
- Role Of CD40 Ligand In Primary Biliary CirrhosisNational Center For Research Resources1998–2002
Committees
- Member, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) 2016 - Present
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
